Drug intelligence / Profile preview

99mTc-YTH 24.5

Development stage
Unknown
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

99mTc-YTH 24.5 is a radiopharmaceutical composed of technetium-99m, a metastable nuclear isomer of technetium-99 used as a gamma-emitting radionuclide, conjugated to YTH 24.5, which is a murine monoclonal antibody. The resulting radioimmunoconjugate is designed for diagnostic imaging, likely in oncological or immunoscintigraphy applications. Technetium-99m serves as a gamma emitter detectable by SPECT imaging, enabling visualization of targets bound by the antibody[1][4]. The specificity of YTH 24.5 typically depends on its antigen target, which is not detailed in the retrieved literature, but this class of agents is primarily used for tumor or cell-surface marker imaging.

Other names
technetium-99m YTH 24.5technetium99m YTH 24.5technetium 99m YTH 24.5Tc-99m YTH 24.5Tc99m YTH 24.5Tc 99m YTH 24.5
02

Targets

PTPRC (Receptor-type tyrosine-protein phosphatase C)

Beyond the preview

Go deeper on 99mTc-YTH 24.5.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 99mTc-YTH 24.5.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call